Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026)
Insight Molecular Diagnostics (IMDX) posted Return on Capital Employed of 213.69% for Q1 2026, down 13.76% sequentially from 187.84% in Q4 2025, and down 8055.0% YoY from 2.69% in Q1 2025.
Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported Return on Capital Employed for 11 years, with the latest figure at 213.69% in Q1 2026.
- Quarterly Return on Capital Employed fell 8055.0% year-over-year to 213.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 213.69% (down 8055.0% YoY) and the FY2025 annual result came in at 278.7%, down 15077.0% from the prior year.
- Return on Capital Employed slipped to 213.69% in Q1 2026 per IMDX's latest filing, from 187.84% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11.13% in Q1 2023 and troughed at 213.69% in Q1 2026.
- A 5-year average of 71.68% and a median of 39.08% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed jumped 3627 bps in 2023, then tumbled 9485 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 15.43% in 2022, then sank by 68 bps to 25.95% in 2023, then sank by 315 bps to 107.72% in 2024, then tumbled by 74 bps to 187.84% in 2025, then declined by 14 bps to 213.69% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 213.69%, 187.84%, and 133.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 8.30% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 6.42% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 68.60% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 14.57% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 10.49% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -16.64% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 17.55% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 49.80% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 10.85% |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 | -213.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -213.69% |
| Dec 31, 2025 | -187.84% |
| Sep 30, 2025 | -133.86% |
| Jun 30, 2025 | -106.56% |
| Mar 31, 2025 | -133.14% |
| Dec 31, 2024 | -107.72% |
| Sep 30, 2024 | -39.02% |
| Jun 30, 2024 | -39.08% |
| Mar 31, 2024 | -45.38% |
| Dec 31, 2023 | -25.95% |
| Sep 30, 2023 | -26.92% |
| Jun 30, 2023 | -20.38% |
| Mar 31, 2023 | -11.13% |
| Dec 31, 2022 | -15.43% |
| Sep 30, 2022 | -27.79% |
| Jun 30, 2022 | -37.32% |
| Mar 31, 2022 | -47.40% |
| Dec 31, 2021 | -49.53% |
| Sep 30, 2021 | -28.09% |
| Jun 30, 2021 | -28.03% |